ArticleEJNMMI reports2026
The role of Choline-PET/CT in patients with recurrent prostate cancer and a negative PSMA-PET/CT.
Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe sensitivity of PSMA-PET/CT for the detection of recurrent prostate cancer (rPC) is good at low PSA values and rapidly rises to > 80% in patients with PSA > 1.5 ng/mL. Currently, there are no general rules on how to manage PSMA-PET-negative patients with rPC and PSA levels at which a pathological PSMA-PET must be considered very likely. The aim of this evaluation was to assess the value of a choline-PET/CT in such a clinical context. MATERIALS AND
methodsWe conducted a retrospective analysis incorporating data from 01/2017–09/2023 from two Swiss institutions. Eligible patients included those with rPC following radical prostatectomy (RP) who had a negative or equivocal [6 8 Ga]Ga-PSMA-11 or [1 8 F]F-PSMA-1007 PET/CT despite a PSA level ≥1.5 ng/mL, and were subsequently referred for [18F]F-Fluorocholine-PET/CT within two months. Two experienced nuclear medicine physicians reviewed both scans (choline and PSMA-PET/CTs) in a blinded consensus read.
resultsEleven patients met all inclusion criteria. The median PSA level was 2.8 ng/mL (range: 1.7–16.0). Following [18F]F-Fluorocholine-PET/CT 6 out of 11 patients (54.5%) demonstrated pathologic choline positive findings indicative of rPC: 4 patients with local recurrence, 1 with distant metastasis only, and 1 with concomitant pelvic lymph node and distant metastases.
conclusionMore than 50% of patients with a negative or equivocal PSMA-PET/CT showed pathologic [18F]F-Fluorocholine-PET/CT. These results indicate that [18F]F-Fluorocholine-PET/CT may serve as a valuable complementary imaging modality in patients with rPC after RP who present with a negative PSMA-PET/CT at PSA levels ≥1.5 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.